← Eichor
Condition: Mesothelin Expressing Tumors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Mesothelin Expressing Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Phase 1 · 7 location(s) · Light Chain Bioscience - Novimmune SA · NCT05403554Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06885697Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
NA · 1 location(s) · Zhejiang University · NCT07010523Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT01950572A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06623396An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
EARLY_Phase 1 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05166070A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
Phase 1 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06760364CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors
NA · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06717022A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT05141253A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Sichuan Huiyu Pharmaceutical Co., Ltd · NCT07083323SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Phase 1 · 5 location(s) · Verismo Therapeutics · NCT05568680
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.